Autophagy-related genes analysis reveals potential biomarkers for prediction of the impaired walking capacity of peripheral arterial disease.
Autophagy
Biomarkers
Growth-related oncogene
Neutrophil activating protein2
Peripheral arterial disease
Treadmill testing
Journal
BMC medicine
ISSN: 1741-7015
Titre abrégé: BMC Med
Pays: England
ID NLM: 101190723
Informations de publication
Date de publication:
18 05 2023
18 05 2023
Historique:
received:
02
01
2023
accepted:
02
05
2023
medline:
19
5
2023
pubmed:
18
5
2023
entrez:
17
5
2023
Statut:
epublish
Résumé
The role of autophagy and autophagy-related genes in peripheral arterial disease (PAD) remains unknown and may be of diagnostic and prognostic value. The aim of this study is to investigate the relationship between autophagy and PAD, and identify potential diagnostic or prognostic biomarkers for medical practice. Differentially expressed autophagy-related genes in PAD were explored from GSE57691 and validated in our WalkByLab registry participants by quantitative real-time polymerase chain reaction (qRT-PCR). The level of autophagy in peripheral blood mononuclear cells (PBMCs) of WalkByLab participants was assessed by analyzing autophagic marker proteins (beclin-1, P62, LC3B). Single sample gene set enrichment analysis (ssGSEA) was used to evaluate the immune microenvironment within the artery wall of PAD patients and healthy persons. Chemokine antibody array and enzyme-linked immunosorbent assay were used to assess the chemokines in participants' plasma. Treadmill testing with Gardner protocol was used to evaluate participants' walking capacity. Pain-free walking distance, maximum walking distance, and walking time were recorded. Finally, a nomogram model based on logistic regression was built to predict impaired walking performance. A total of 20 relevant autophagy-related genes were identified, and these genes were confirmed to be expressed at low levels in our PAD participants. Western blotting demonstrated that the expression of autophagic marker proteins beclin-1 and LC3BII were significantly reduced in PAD patients' PBMCs. ssGSEA revealed that most of the autophagy-related genes were strongly correlated with immune function, with the largest number of associated genes showing interaction between cytokine-and-cytokine receptors (CCR). In this context, the chemokines growth-related oncogene (GRO) and neutrophil activating protein2 (NAP2) are highly expressed in the plasma of WalkByLab PAD patients and were significantly negatively correlated with the walking distance assessed by Gardner treadmill testing. Finally, the plasma NAP2 level (AUC: 0.743) and derived nomogram model (AUC: 0.860) has a strong predictive potential to identify a poor walking capacity. Overall, these data highlight both the important role of autophagy and autophagy-related genes in PAD and link them to vascular inflammation (expression of chemokines). In particular, chemokine NAP2 emerged as a novel biomarker that can be used to predict the impaired walking capacity in PAD patients.
Sections du résumé
BACKGROUND
The role of autophagy and autophagy-related genes in peripheral arterial disease (PAD) remains unknown and may be of diagnostic and prognostic value. The aim of this study is to investigate the relationship between autophagy and PAD, and identify potential diagnostic or prognostic biomarkers for medical practice.
METHODS
Differentially expressed autophagy-related genes in PAD were explored from GSE57691 and validated in our WalkByLab registry participants by quantitative real-time polymerase chain reaction (qRT-PCR). The level of autophagy in peripheral blood mononuclear cells (PBMCs) of WalkByLab participants was assessed by analyzing autophagic marker proteins (beclin-1, P62, LC3B). Single sample gene set enrichment analysis (ssGSEA) was used to evaluate the immune microenvironment within the artery wall of PAD patients and healthy persons. Chemokine antibody array and enzyme-linked immunosorbent assay were used to assess the chemokines in participants' plasma. Treadmill testing with Gardner protocol was used to evaluate participants' walking capacity. Pain-free walking distance, maximum walking distance, and walking time were recorded. Finally, a nomogram model based on logistic regression was built to predict impaired walking performance.
RESULTS
A total of 20 relevant autophagy-related genes were identified, and these genes were confirmed to be expressed at low levels in our PAD participants. Western blotting demonstrated that the expression of autophagic marker proteins beclin-1 and LC3BII were significantly reduced in PAD patients' PBMCs. ssGSEA revealed that most of the autophagy-related genes were strongly correlated with immune function, with the largest number of associated genes showing interaction between cytokine-and-cytokine receptors (CCR). In this context, the chemokines growth-related oncogene (GRO) and neutrophil activating protein2 (NAP2) are highly expressed in the plasma of WalkByLab PAD patients and were significantly negatively correlated with the walking distance assessed by Gardner treadmill testing. Finally, the plasma NAP2 level (AUC: 0.743) and derived nomogram model (AUC: 0.860) has a strong predictive potential to identify a poor walking capacity.
CONCLUSIONS
Overall, these data highlight both the important role of autophagy and autophagy-related genes in PAD and link them to vascular inflammation (expression of chemokines). In particular, chemokine NAP2 emerged as a novel biomarker that can be used to predict the impaired walking capacity in PAD patients.
Identifiants
pubmed: 37198605
doi: 10.1186/s12916-023-02889-5
pii: 10.1186/s12916-023-02889-5
pmc: PMC10193747
doi:
Substances chimiques
Beclin-1
0
Biomarkers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
186Informations de copyright
© 2023. The Author(s).
Références
Oncotarget. 2015 May 30;6(15):12984-96
pubmed: 25944698
Nat Rev Cardiol. 2017 Mar;14(3):156-170
pubmed: 27853158
J Pharmacol Exp Ther. 2009 Feb;328(2):458-68
pubmed: 19004925
J Radiat Res. 2017 Jul 1;58(4):421-429
pubmed: 28201773
Lancet. 2013 Oct 19;382(9901):1329-40
pubmed: 23915883
Vasa. 2021 Nov;50(6):413-422
pubmed: 34428929
Nutrients. 2019 Jul 29;11(8):
pubmed: 31362417
Mol Biol Rep. 2014 Jul;41(7):4389-95
pubmed: 24599781
BMJ Open Diabetes Res Care. 2020 Apr;8(1):
pubmed: 32327445
Front Neurol. 2020 Jan 15;10:1391
pubmed: 32010048
Arterioscler Thromb Vasc Biol. 2020 Jul;40(7):1627-1634
pubmed: 32434408
Brain Behav. 2017 Jul 07;7(8):e00746
pubmed: 28828208
Basic Res Cardiol. 2020 Jun 6;115(4):41
pubmed: 32506214
Circ Res. 2018 Sep 14;123(7):803-824
pubmed: 30355077
Placenta. 2018 Jun;66:47-56
pubmed: 29884302
Cell. 2015 Jan 15;160(1-2):48-61
pubmed: 25594174
Exp Biol Med (Maywood). 2019 Jan;244(1):22-27
pubmed: 30638058
Cell Metab. 2012 Apr 4;15(4):534-44
pubmed: 22440612
Int J Environ Res Public Health. 2022 Sep 07;19(18):
pubmed: 36141513
Clin Transl Med. 2017 Dec;6(1):24
pubmed: 28748360
Front Pharmacol. 2015 Aug 25;6:179
pubmed: 26379552
Front Physiol. 2020 Sep 25;11:576463
pubmed: 33101057
Circ Res. 2015 Jan 30;116(3):468-79
pubmed: 25634970
Arch Pathol Lab Med. 2000 Apr;124(4):520-5
pubmed: 10747307
Sci Rep. 2018 Jul 13;8(1):10647
pubmed: 30006564
Biochim Biophys Acta. 2015 Feb;1852(2):243-51
pubmed: 24834848
J Vasc Surg. 2018 Oct;68(4):1126-1134
pubmed: 29615353
BMC Bioinformatics. 2013 Jan 16;14:7
pubmed: 23323831
Atherosclerosis. 2014 Mar;233(1):211-8
pubmed: 24529146
Coron Artery Dis. 2013 Dec;24(8):651-6
pubmed: 24212263
Biomed Res Int. 2019 Jul 18;2019:3026453
pubmed: 31396527
Cell Death Dis. 2020 Aug 14;11(8):624
pubmed: 32796816
Proc Am Thorac Soc. 2010 Feb;7(1):40-7
pubmed: 20160147
J Physiol Pharmacol. 2016 Apr;67(2):321-8
pubmed: 27226191
Free Radic Biol Med. 2017 Aug;109:108-113
pubmed: 27940349
Int J Biol Sci. 2020 Jul 6;16(13):2430-2441
pubmed: 32760210